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Abstract
Background: Neoplasia can be driven by mutations resulting in dysregulation of transcription. In the
mesenchymal neoplasm, aggressive fibromatosis, subtractive hybridization identified sterile alpha motif
domain 9 (SAMD9) as a substantially down regulated gene in neoplasia. SAMD9 was recently found to be
mutated in normophosphatemic familial tumoral calcinosis. In this study, we studied the gene structure
and function of SAMD9, and its paralogous gene, SAMD9L, and examined these in a variety of species.
Results: SAMD9 is located on human chromosome 7q21.2 with a paralogous gene sterile alpha motif
domain 9 like (SAMD9L) in the head-to-tail orientation. Although both genes are present in a variety of
species, the orthologue for SAMD9 is lost in the mouse lineage due to a unique genomic rearrangement.
Both SAMD9 and SAMD9L are ubiquitously expressed in human tissues. SAMD9 is expressed at a lower
level in a variety of neoplasms associated with β-catenin stabilization, such as aggressive fibromatosis,
breast, and colon cancers. SAMD9 and SAMD9L contain an amino-terminal SAM domain, but the remainder
of the predicted protein structure does not exhibit substantial homology to other known protein motifs.
The putative protein product of SAMD9 localizes to the cytoplasm. In vitro data shows that SAMD9
negatively regulates cell proliferation. Over expression of SAMD9 in the colon cancer cell line, SW480,
reduces the volume of tumors formed when transplanted into immune-deficient mice.
Conclusion:  SAMD9 and SAMD9L are a novel family of genes, which play a role regulating cell
proliferation and suppressing the neoplastic phenotype. This is the first report as far as we know about a
human gene that exists in rat, but is lost in mouse, due to a mouse specific rearrangement, resulting in the
loss of the SAMD9 gene.
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Background
Neoplasia can be driven by a variety of mechanisms. In
many cases, oncogenic mutations result in the dysregula-
tion of transcription. This is the case in mutations result-
ing in β-catenin stabilization in tumors, as stabilized β-
catenin activates transcription factors in the Tcf/Lef fam-
ily. These transcription factors regulate gene expression in
a tissue specific manner [1,2]. Aggressive fibromatosis,
also known as desmoid tumor, is a locally invasive soft tis-
sue tumor composed of a clonal proliferation of mesen-
chymal, fibroblast-like, cells [3]. Somatic mutations in
either the Adenomatous Polypisis Coli (APC) or β-catenin
genes, resulting in the stabilization of β-catenin protein,
are present in the majority of lesions. This gives aggressive
fibromatosis tumor cells a proliferative advantage
through Tcf/Lef dependent transcriptional activation
[4,5]. There are a variety of lines of evidences suggesting
that differentially expressed genes in aggressive fibroma-
tosis are involved in the development of this tumor. For
instance, the differentially expressed genes, COX-2,
RHAMM, MMP-3, TIMP-1 and PAI-1 modulate the size or
number of aggressive fibromatosis tumor that form [6-9].
To determine how differentially regulated genes contrib-
ute to the neoplastic phenotype in aggressive fibromato-
sis, suppression subtractive hybridization was used to
compare gene expression differences between cell cultures
derived from an aggressive fibromatosis tumor with an
APC  mutation and the same cells after transfection of
wild-type APC. In this comparison, we found that SAMD9
was one of the most highly differentially regulated genes,
and was upregulated with transfection of the wild-type
APC. This study focuses on the gene structure and func-
tion of SAMD9 and its paralogous gene, SAMD9L.
Results
SAMD9 is differentially regulated in aggressive 
fibromatosis
Primary cell cultures from an aggressive fibromatosis
tumor harbouring a truncating APC mutation were estab-
lished. These were transfected with either a wild-type APC
gene or a control vector, and successful transfection veri-
fied using immunohistochemistry. These cell cultures
were established for a previous study to determine the role
of the interaction between APC and β-catenin in the regu-
lation of cell proliferation in aggressive fibromatosis. The
transfection conditions, mutational analysis, and results
of proliferation studies have been previously reported
[10,11]. RNA from the cells derived from an aggressive
fibromatosis tumor with an APC mutation and the same
cells after transfection of wild-type APC were compared
using suppression subtractive hybridization. Both forward
(cells transfected with a control vector compared to cells
transfected with wild-type APC) and reverse (cells trans-
fected with wild-type APC compared to cells transfected
with a control vector) subtractions were conducted.
Clones were identified, and verified using Northern blot.
The most differentially expressed clones were sequenced
and their identity searched using GenBank.
In this comparison, the most differentially regulated gene
in the reverse subtraction was a novel gene that was ini-
tially identified on human chromosome 7 using GenBank
sequence data. Both 5'- and 3'- rapid amplification of
cDNA ends (RACE) using the sequence of the 200 bp
clone isolated from suppression subtractive hybridiza-
tion, as well as analysis of EST in the region were under-
taken to identify the full length of this gene. Subsequent
to the start of this work, Strausberg et al identified a gene
in this region using high through put analysis of EST's and
designed the gene sterile alpha motif domain 9 (SAMD9)
[12]. During this analysis, we also found a nearby gene,
which was also subsequently identified by Strausberg et al
as sterile alpha motif domain 9 like (SAMD9L) [12].
Using a search of the DNA sequence database in GenBank,
SAMD9 and SAMD9L were found to match human chro-
mosome 7q21.2. SAMD9L is located 5' upstream from the
SAMD9 gene (Fig. 1). Both genes are coded by the reverse
strand with a head to tail orientation.
Structure of SAMD9 and its paralogue – SAMD9L
Compiling all of the sequence data, we located the most
5'- end sequence for SAMD9 in a 5'- RACE clone, and the
most 3'- end sequence for SAMD9 in one of the EST clones
[GenBank: AA628487] [see Additional file 1]. Using prim-
ers corresponding to the sequences of the most 5'- and 3'-
ends of the SAMD9 gene, a predicted 7 kb transcript was
amplified from an aggressive fibromatosis tumor cDNA.
The full-length of this transcript, the longest transcript
that we found, was sequenced [GenBank: AF445355]. The
cDNA sequence of SAMD9 gene has 6847 bp with a poly-
A signal (AATAAA) at 6831 bp downstream from the tran-
scriptional start point (Fig. 1A). Mapping this cDNA
sequence to the genomic DNA sequence in the GenBank,
the SAMD9 gene is 18505 bp in length and contains three
exons (161 bp, 101 bp and 6585 bp in length, respec-
tively). There is a TATA signal (CCTATATTCT) at -75 bp
and five predicted Lef/Tcf binding elements [(C,G) (A,T)
(A,T)CAAA(G,C)] at -11440 bp, -10247 bp, -8014 bp, -
4788 bp and -3321 bp. The clones isolated from 5'- and
3'- RACE of the SAMD9 gene were sequenced. Comparing
the 5'- and 3'- RACE sequences to the genomic DNA
sequence from GenBank, different transcription initiation
sites and polyadenylation sites of SAMD9 are noted, and
there are at least two alternative splices.
During the analysis of EST sequences near the initial
clone, we identified a second gene,SAMD9L, which is
located 12740 bp distal to SAMD9. Using the sequences
from the most 5'- and 3'- EST in the region [Celera Data-BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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Gene and protein structure of SAMD9 and SAMD9L Figure 1
Gene and protein structure of SAMD9 and SAMD9L. A. Diagram of SAMD9 gene structure and predicted protein struc-
ture. Exons are shown as red rectangles. The protein is shown in green, with the sterile alpha motif domain as blue oval. B. 
Diagram of SAMD9L gene structure and predicted protein structure. Exons are shown in red. The protein is shown as a pink 
box, with two predicted open reading frames of shown. The sterile alpha motif domain is shown as blue oval. A potential 
nuclear localization domain is shown as grey box.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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base: THC 511215 and THC 513290, respectively] [see
Additional file 1], the full-length sequence of the SAMD9L
was amplified from an aggressive fibromatosis tumor
cDNA, and sequenced [GenBank: AF474973]. The cDNA
sequence of SAMD9L gene has 5821 bp with a poly-A sig-
nal (AATAAA) at 5659 bp downstream from the transcrip-
tional start point (Fig. 1B). Mapping this cDNA sequence
to the genomic DNA sequence in GenBank, the SAMD9L
gene is 17583 bp in length, including six exons (152 bp,
59 bp, 132 bp, 148 bp, 102 bp and 5228 bp in length,
respectively). There is a TATA signal (TCTATACTTC) at -73
bp and two predicted Lef/Tcf binding elements [(C,G)
(A,T) (A,T)CAAA(G,C)] at -49139 bp and -3661 bp.
There are alternatively spliced transcripts in both SAMD9
[GenBank: AF453311] and SAMD9L  [GenBank:
AY195582-195587, DQ068177] [see Additional file 1].
These alternative splices lead to either inclusion or exclu-
sion of an exon due to the usage of a different 5' donor
splice site or a different 3' acceptor splice site. This alterna-
tive splicing also changes the internal coding region due
to an in-frame insertion or deletion in both SAMD9 and
SAMD9L. In the case of SAMD9, non-canonical dinucle-
otides AT and TC are used as donor and acceptor splice
sites for intron 3, and there is an in-frame canonical pair
of the donor and acceptor (GT and AG) splice sites near
by. This alternative splicing changes the internal coding
region due to an in-frame deletion, leading to the exclu-
sion of sequence coding for a putative protein structure
domain – sterile alpha motif (SAM) domain near the N-
terminus.
The putative protein structures of both genes were deter-
mined using the open reading frame finder program on
the National Center for Biotechnology Information
(NCBI) website [13], and an open reading frame was
identified in the last exon of both genes. The two genes
share 78% homology at the DNA sequence level in this
exon. The putative protein sequences were analyzed using
the Conserved Domain search program in NCBI website
[14] for SAMD9, the Motif Scan program from Swiss Insti-
tute of Bioinformatics [15-17] and the Predict Protein
server from European Molecular Biology Laboratory [18]
websites for SAMD9L. Both protein products contain a
sterile alpha motif (SAM) domain near the N-terminal
region. Otherwise, there is no close homology to other
well-characterized proteins or protein motifs. Based on a
comparison of the SAM domain sequence of SAMD9 to
the homology modeling of the RNA-binding Smg SAM
domain [19], the SAM domain of SAMD9 lacks the resi-
dues that are essential for binding RNA, while it has 98%
sequence homology with the Ephrin-B2-receptor SAM
domain, which forms homo-oligomerization and pro-
vides a platform for the formation of larger protein com-
plexes [20].
SAMD9 and SAMD9L are ubiquitously expressed
The expected 7 kb transcript of SAMD9 was identified by
Northern analysis using RNA from different age placentas
and a 1729 bp PCR amplified probe encompassing the
3'UTR (Fig. 2A). The expression pattern of SAMD9 in mul-
tiple tissues was investigated using a human multiple tis-
sue cDNA panel (Clontech, USA) and RT-PCR. The
primers were designed to recognize sequences at 3'UTR of
SAMD9. Expression was detected in all human adult, fetal
and tumor tissues that were tested, except for fetal brain.
Only a very low signal was detected in skeletal muscle
(Fig. 2B). Using the sequences at 3'UTR of SAMD9L as
primers, SAMD9L was also found to be expressed in all tis-
sues, except for the tumor types, colon cancer (CX-1),
breast cancer (GI-101) and pancreatic cancer (GI-103)
(Fig. 2B).
SAMD9 and SAMD9L are expressed at lower levels in 
tumors
To determine the level of expression of SAMD9 in neopla-
sia, semi-quantitative RT-PCR and real-time quantitative
PCR were performed using the sequence at 5'UTR of
SAMD9 as a sense primer and a sequence at the beginning
of the open reading frame of SAMD9  as an anti-sense
primer. Expression was compared between tumor and
normal control tissues in cases of aggressive fibromatosis,
breast cancer and colon cancer. SAMD9 was expressed at
a lower level (about 33% the level for normal control tis-
sues) in aggressive fibromatosis (32.22% ± 29.18% vs
100%, p < 0.05 for real-time PCR, Fig. 3A). Expression of
SAMD9 was lower in 20% cases of breast cancer and 35%
cases of colon cancer than in the normal control tissues
(Fig. 3C). In three cases of colon cancer, there was no RT-
PCR product detected. However, there was no significant
difference in expression between colon cancers and nor-
mal control tissues or breast cancers and normal control
tissues when analysed as a group using real-time PCR.
Expression studies of SAMD9L were also conducted using
a sequence at 5'UTR which is common for all of the splice
variants except one, as a sense primer and sequence at the
beginning of the open reading frame as an anti-sense
primer. There was no statistically significant difference in
SAMD9L expression between aggressive fibromatosis or
colon cancer and normal control tissues. However, the
expression of SAMD9L was lower in breast cancers than in
healthy breast epithelial tissues from the same patients
(2.81% ± 2.40% vs 100%, n = 10, p < 0.001, Fig. 3B).
There was no significant difference in expression of
SAMD9L  between aggressive fibromatosis samples and
normal controls tissues (Fig. 3D). While two genes are
expressed at a lower level in tumors, there is a discrepancy
between the levels of expression of the two genes in differ-
ent tumor types. For instance, SAMD9  is expressed at
lower levels in aggressive fibromatosis, while SAMD9L is
not.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
Page 5 of 17
(page number not for citation purposes)
Expression of SAMD9 and SAMD9L in multiple tissue types Figure 2
Expression of SAMD9 and SAMD9L in multiple tissue types. A. Northern blot from total RNA of 8 weeks, 12 weeks 
and full term human placenta probed with 3'UTR of SAMD9. A 7 kb transcript was detected in full term human placenta. B. 
Human adult, fetal, and tumor multiple tissue cDNA panels were amplified with the sequences at 3'UTR of SAMD9, SAMD9L or 
GAPDH as primers. SAMD9 was expressed in all human adult, fetal and tumor tissues that were available from human multiple 
tissue cDNA panels except for fetal brain and breast cancer. It was expressed at a very low level in skeletal muscle and pancre-
atic cancer. SAMD9L is expressed in all human adult, fetal and tumor tissues that were available from human multiple tissue 
cDNA panels, except breast cancer, colon cancer, and pancreatic cancer.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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Lower level of expression of SAMD9 and SAMD9L in neoplasia Figure 3
Lower level of expression of SAMD9 and SAMD9L in neoplasia. A. Validation curves for the primer sets of SAMD9 and 
28S rRNA, and real time quantitative PCR of SAMD9. SAMD9 and 28S rRNA have similar amplification efficiency since the slope 
was very similar for both curves. SAMD9 was expressed at a lower level in aggressive fibromatosis (AF) tumors compared to 
normal fibrous tissues from same patients. B. Validation curves for the primer sets of SAMD9L and 28S rRNA, and real time 
quantitative PCR of SAMD9L. SAMD9L and 28S rRNA have similar amplification efficiency since the slope was very similar for 
both curves. SAMD9L was expressed at a lower level in breast cancers compared to normal breast epithelial tissues from same 
patients.C. Semi-quantitative RT-PCR of SAMD9. SAMD9 was under-expressed in some cases of colon cancer compared to the 
normal colon mucosa from same patients. Real time PCR data showed no significant difference in expression level between 
breast and colon cancer and normal controls as a group. D. There was no significant difference in expression of SAMD9L 
between aggressive fibromatosis samples and normal controls tissues.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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SAMD9 is a cytoplasmic protein
In order to investigate the cellular localization of the puta-
tive  SAMD9  protein, the open reading frame of the
SAMD9 gene was cloned, an N-terminal EGFP tag was
added and subcloned into a CMV driven vector pLP-
EGFP-C1 (Clontech, USA). This vector was transfected
into Cos-1 cells, and using an antibody to EGFP, the
fusion protein was detected as a 200 kDa band (Fig. 4A).
To determine its localization in a variety of cell types, it
was transfected into a human fetal fibroblast cell line,
MRC-5, and a colon cancer cell line, SW480. The EGFP
fusion protein was detected diffusely in the cell cytoplasm
(Fig. 4B–F).
RNAi for SAMD9 can be used to down regulate its 
expression
RNA interference was utilized to study the cellular func-
tion of SAMD9. RNA interference was designed by search-
ing the public available sequence database to find a 19 bp
oligonucleotide sequence specific for SAMD9 and insert-
ing into a pSUPER-RNAi-EGFP expression vector to gener-
ate the SAMD9 RNA interference vector (pSUPER-RNAi-
SAMD9). One of the sequences is 846 bp after the start of
translation, and other is 2371 bp after the start of transla-
tion. The pSUPER-RNAi-EGFP expression vector was gen-
erated based on pEGFP-C1 (Clontech, USA) and pSUPER
[21]. A nucleotide substitution from G to A at the 9th posi-
tion of this 19 bp oligonucleotide results in abolishing of
its specificity to SAMD9 and was used as negative control
after subcloned into a pSUPER-RNAi-EGFP expression
vector to generate the negative control vector (pSUPER-
RNAi-SAMD9-mut9).
SAMD9 expression reduced by RNA interference vector for
SAMD9 was tested by co-transfection of an N-terminal
EGFP tagged SAMD9 expression vector with either one of
the two SAMD9 RNA interference vectors, RNA interfer-
ence vector with mutated SAMD9  sequence to null its
function as negative control, or its control empty vector
into Cos-1 cells. The reduction of SAMD9 expression was
confirmed using Western blot with anti-GFP (Santa Cruz,
USA) for the fusion putative SAMD9  protein. A 90%
reduction in expression of SAMD9 fusion protein by RNA
interference was detected as measured using densitometry
(Fig. 5A). The RNA interference vector that express EGFP
was also expressed in SW480 cells along with an N-termi-
nal HA tagged SAMD9 expression vector or its control vec-
tor. A 90% reduction in expression of SAMD9  fusion
protein by RNA interference was detected (data not
shown). Activity of the RNA interference vector for
SAMD9 was further verified by the reduction of SAMD9
RNA expression in MRC-5 cells (Fig. 5B).
SAMD9 regulates cell proliferation and apoptosis
Because  β-catenin stabilization is known to regulate
fibroblast proliferation, motility and invasiveness [11],
we studied the effect of down-regulating SAMD9 on these
parameters. Proliferation rate, as measured by BrdU incor-
poration, was increased after RNA interference of SAMD9
in MRC-5 cells (12.5% ± 2.66% with the 1st SAMD9 RNA
interference vector, 12.2% ± 1.63% with the 2nd SAMD9
RNA interference vector, and 7.5% ± 1.29% with the con-
trol vector, p < 0.01, Fig. 5C). There was not a statistical
difference in cell motility as measured by the number of
cells passing through the membrane of the culture insert
(1.7 ± 0.65 or 2.3 ± 1.31 with RNA interference of SAMD9
vector vs 0.67 ± 0.65 with control vector). Cell invasion
was increased, as measured by the number of cells passing
through the membrane of the Matrigel invasion cham-
bers, after SAMD9  expression was decreased in MRC-5
cells by RNA interference (16 ± 5.19 with RNA interfer-
ence of SAMD9 vector vs 5.7 ± 1.73 with control vector, p
< 0.05). These studies were also undertaken in Cos-1 cells,
and showed a similar reduction in proliferation rate after
over-expression of the putative SAMD9 protein in Cos-1
cells (20.7% ± 21.9% vs 76.8% ± 20.2%, p < 0.005).
Taken together, this shows that SAMD9 plays a role regu-
lating cell proliferation.
To explore the effect in neoplasia, cells from the SW480
colon cancer cell line were transfected with a SAMD9
expression vector to determine if increasing expression of
this gene would suppress the neoplastic behavior in these
cells. Upon transfection of the construct, cell proliferation
was reduced (25.6% ± 3.3% vs 46.2% ± 9.4%, p < 0.01,
Fig. 6A). Cell invasion index calculated as the ratio of the
total number of nuclei counted in the membrane for inva-
sion assay to that in the membrane for motility assay was
reduced (0.0335 ± 0.0203 vs 0.0779 ± 0.0183, p < 0.05,
Fig. 6B), while cell apoptosis, as indirectly measured by
relative caspase-3 activity was increased (253.11% ±
45.90% of baseline, p < 0.005, Fig. 6C). The relative cas-
pase-3 activity was also reduced in Cos-1 cells after expres-
sion of the SAMD9 siRNA construct (53.76% ± 0.99% of
the baseline, p < 0.01). Thus expressing SAMD9 at higher
levels causes cell effects which would be expected to sup-
press the neoplastic phenotype.
SAMD9 regulates tumor growth
To investigate the role of SAMD9 in tumor growth, the
colon cancer cell line, SW480, was transfected with
SAMD9 expression vector or its control empty vector. The
stably transfected SW480 cells were injected into the
immune deficient mice. The tumor volume of the
xenograft from SW480 cells over-expressing SAMD9 was
reduced in both nude mice (62.5 ± 73.5 mm3 vs 162.5 ±
61.7 mm3, n = 4, p < 0.05, Fig. 6D) and NOD-SCID mice
(62.4 ± 20.3 mm3 vs 98.6 ± 17.1 mm3, n = 21, p < 0.01,BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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Fig. 6E). To verify the role of SAMD9 on neoplasia, we per-
formed experiments when the expression of SAMD9 was
lowered using RNA interference. The tumor volume of the
xenograft from SW480 cells expressing the RNA interfer-
ence of SAMD9 was increased in nude mice (310 ± 19.6
mm3 vs 270 ± 24 mm3, n = 5, p < 0.05).
Orthologous genes of SAMD9 and SAMD9L
The orthologous genes were identified for SAMD9 and
SAMD9L by searching the NR and swissprot databases for
best reciprocal matches using human SAMD9  and
SAMD9L  protein sequences. Genome sequences for all
species available were searched by BLAT at the University
of California at Santa Cruz genome browser [22]. The
results were summarized in Table 1 and the phylogram
[see Additional File 1] was constructed using multiple
sequence alignment of orthologous genes identified with
ClustalW program from European Bioinformatics Insti-
tute website [23]. The default parameters from website
documentation were used [24]. Based on their sequence
similarity,  SAMD9  and  SAMD9L  appear to have origi-
nated from a common ancestor by an ancient gene dupli-
cation. Since there are orthologous genes of both SAMD9
and SAMD9L in chimpanzees, dogs and rats, but not in
chicken, frog or fish species, this duplication event likely
occurred after the mammalian radiation. The genomic
structures of both SAMD9 and SAMD9L, including the
order and orientation of genes within the genomic region
and the relative size of the intergenic region, are conserved
in all available mammalian genome sequences including
SAMD9 protein is expressed and localized to the cytoplasm Figure 4
SAMD9 protein is expressed and localized to the cytoplasm. A. Western analysis for the SAMD9-EGFP fusion protein. 
The SAMD9 fusion protein was detected as a predicted 200 kDa band in Cos-1 cells, using an antibody to GFP. B, C. Expres-
sion of SAMD9 putative protein in MRC-5 cells. N-terminal EGFP tagged SAMD9 was detected in the cytoplasm of MRC-5 cells 
when transiently transfected. B. Light field view. C. Fluorescent microscopy view for FITC. D, E, F. Expression of SAMD9 
putative protein in SW480 cells. N-terminal EGFP tagged SAMD9 localized to the cytoplasm of SW480 cells. D. Fusion protein 
detected under fluorescent wave length for FITC. E. Cell nucleus detected under fluorescent wave length for DAPI. F. Merged 
view of image D and E.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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SAMD9 regulates cell proliferation Figure 5
SAMD9 regulates cell proliferation. A. RNAi for SAMD9 is effective in reducing protein expression. A 200 kDa band for 
the SAMD9 fusion protein was detected in Cos-1 cells after co-transfection of pLP-EGFP-SAMD9 with either pSUPER-RNAi-
SAMD9-mut9 or pSUPER-RNAi-EGFP, but it is not detected after co-transfection with either pSUPER-RNAi-SAMD9 or pSU-
PER-RNAi-SAMD9-2nd. The expression of the EGFP-SAMD9 fusion protein was reduced in Cos-1 cells with RNA interference 
of SAMD9. B. Semi-quantitative RT-PCR for SAMD9 expression in MRC-5 cells. SAMD9 expression was reduced after RNA 
interference. C. Proliferation rate (Brdu incorporation percent) increased after RNA interference of SAMD9 in MRC-5 cells.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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opossum, indicating the gene duplication event occurred
between 175 to 200 MYA [25]. No evidence for either
gene was found in lower eukaryotes such as Drosophila,
C. elegans or yeast.
SAMD9 is lost in the mouse lineage
There were several overlapping ESTs matching the open
reading frame for SAMD9L, and no ESTs corresponding to
the open reading frame for SAMD9 in the mouse genome.
This was confirmed by bioinformatic searches of all
genomic sequences and partial genome sequences (EST
libraries). The 168 kb region in human chromosome 7, in
which  SAMD9  is located, has no match in the mouse
genome. A syntenic map of the region was constructed for
human, mouse and rat. A break of synteny at the SAMD9
locus was determined in mouse, with distal genes map-
ping to mouse chromosome 6, and the proximal genes
mapping to mouse chromosome 5. The mouse specific
rearrangement resulted in new centromere formation at
the site of breakage and the subsequent loss of the SAMD9
gene. The SAMD9L region contains numerous gaps in the
mouse genome assembly, and an enrichment of mouse
SAMD9 reduces tumor size Figure 6
SAMD9 reduces tumor size. A. Increased expression of SAMD9 reduced SW480 cell proliferation rate as detected by Brdu 
incorporation percent. B. Increased expression of SAMD9 reduced the invasion index of SW480 cells. C. Increased expression 
of SAMD9 increased caspase activity in SW480 cells. D and E. The tumor volume formed from SW480 xenografts was 
reduced with increased expression of SAMD9 when transplanted into nude mice (D) or Nod-scid mice (E).BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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specific segmental duplications (Fig. 7, also see Additional
file 1). The relatively poor draft quality of the rat genome
does not allow for high resolution mapping of this locus,
but there is evidence to support the existence of both
SAMD9 and SAMD9L genes in rats with no large genomic
rearrangements, segmental duplications or breaks in syn-
teny although numerous gaps do exist (Fig. 7, also see
Additional file 1). There are no gaps or segmental duplica-
tions at this locus in the human genome, determined by
searching the Human Genome Segmental Duplication
Database.
Discussion
Here we identified a novel gene SAMD9 and its paralogue
SAMD9L located in human chromosome 7q21.2. These
genes are expressed ubiquitously in human tissues.
SAMD9 is expressed at a lower level in aggressive fibroma-
tosis and some cases of breast and colon cancer, while
SAMD9L is expressed at a lower level in breast cancer,
compared to normal control tissues from the same
patients. The putative protein of SAMD9 is localized in the
cytoplasm. Our in vitro data suggests SAMD9 regulates cell
proliferation rate in both normal and tumor cell lines.
Over-expression of SAMD9 in SW480 cells reduced the
volume of tumors that formed in nude mice and NOD-
SCID mice, while the decreased expression in SW480 cells
increased the tumor volume formed in nude mice suggest-
ing a role suppressing the neoplastic phenotype.
Very recently, it was found that SAMD9 is mutated in the
inherited condition, normophosphatemic familial
tumoral calcinosis [26]. In the work of Topaz et al, there is
a likely inadvertent error, as when comparing the protein
sequences in the publication with the swissProt/NCBI
database, it was found that the mouse SAMD9 sequence
reported is actually a predicted rat SAMD9  protein
sequence [GenBank: XP_575365] and the rat SAMD9
sequence reported is the rat predicted SAMD9L protein
sequence [GenBank: XP_001069386]. While conclusions
in their manuscript on the species conservation of SAMD9
are incorrect, the occurrence of soft tissue lesions in this
inherited condition supports our notion that SAMD9
plays an important role in cell processes that are impor-
tant in neoplasia.
There are alternatively spliced transcripts in both SAMD9
and  SAMD9L. The mechanism for alternative splice of
SAMD9 is unusual in that it uses the non-canonical dinu-
cleotides AT and TC as donor and acceptor splice sites for
intron 3, and there is an in-frame canonical pair of the
donor and acceptor (GT and AG) splice sites near by.
Although only the canonical GT-AG, and the non-canon-
ical GC-AG and AT-AC pairs can recruit the splicing
machinery effectively, Burset et al suggested that the other
non-canonical pairs can function exclusively in associa-
tion with a canonical pair, which shares its properties with
the neighbour, as some kind of parasitic splice sites [27].
This alternative splice results in the in-frame deletion of
the sequence coding for the sterile alpha motif (SAM)
domain near the N-terminus of SAMD9. Although it is
only detected in a quarter of the normal and tumor tissues
tested, it has potential to play a dominate-negative role in
the functioning of the main common SAMD9 transcript
with the SAM domain. The alternative splicing increases
the functional complexity of this novel gene, but the func-
tion significance of these alternative splicing variants
needs further investigation.
While we did not investigate the regulation of expression
in SAMD9 and SAMD9L, there are Lef/Tcf binding ele-
ments predicted in the genomic sequence upstream of the
transcriptional start point for both genes. We also found
that the expression of these genes is disregulated in neo-
plasms driven by β-catenin mediated signaling. Although
Table 1: Summary of orthologous genes of SAMD9 and SAMD9L in multiple species
SAMD9 SAMD9L
Species Accession Species Accession
Human GenBank: NP060124.2 Human GenBank:NP_689916.1
Chimpanzee aligns to genomeb Chimpanzee GenBank:XP_527818.1
Dog aligns to genomeb Dog GenBank:XP_539422.1
Rat GenBank:XP_575365.1 Rat GenBank:XP_575369.1
Mouse nonea Mouse GenBank:XP_620286.1
Chicken GenBank:XP_418660.1 Chicken nonea
Cow GenBank:XP_592017.1 Cow nonea
Zebrafish GenBank:XP_698198.1 Zebrafish nonea
Xenopus tropicalis GenBank:AAH91702 Xenopus tropicalis nonea
Xenopus laevis GenBank:AAH94169 Xenopus laevis nonea
Tetraodon nigroviridis GenBank:CAF92907 Tetraodon nigroviridis nonea
a There is no match in protein or nucleotide database. b There is best reciprocal nucleotide match found in genomic sequence.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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this suggests SAMD9 may be regulated by β-catenin, for-
mal promoter studies are needed to verify this possibility.
There is an N-terminal sterile alpha motif (SAM) domain
in the predicted putative proteins of SAMD9  and
SAMD9L. The SAM domain sequence of SAMD9 was com-
pared using the homology modeling of the RNA-binding
Smg SAM domain [19]. This showed that the SAM domain
lacks the residues that are essential for binding RNA, while
it has 98% sequence homology with the Ephrin-B2-recep-
tor SAM domain, which is important in homo-oligomeri-
zation and acts as a platform for the formation of larger
protein complexes [20]. This raises the possible that
SAMD9 may have a similar function participating in pro-
tein complexes.
Human chromosome 7q21.2 is located at an evolutionary
breakpoint between mouse chromosome 5 and 6, which
was localized after human-mouse comparative mapping
of the genomic region containing CDK6, i.e., human
genes' centromeric to CDK6 map to proximal mouse chro-
mosome 5, while those telomeric to the open reading
frame for SAMD9L, map to proximal mouse chromosome
6 [28]. Based on our bioinformatics analysis, there are
chimpanzee, dog, and rat orthologous genes for both
SAMD9 and SAMD9L. Although there is a mouse ortholog
of SAMD9L, SAMD9 is lost in the mouse genome. This is
the first report as far as we know about a human gene that
exists in rat, but is lost in mouse.
Four human genes, collagen XXI (COL21A1), serine-thre-
onine kinase family member (STK17A), G-protein cou-
pled receptor family member (GPR145) and ras
homologue gene family member I (ARH I), located in
regions corresponding to evolutionary breakpoints in
rodents are absent in both mouse and rat genomes due to
an unexpected consequence of evolutionary chromosome
rearrangement at the evolutionary breakpoint and lost
during evolution [29]. SAMD9 locates in a 168 kb region
on human chromosome 7, which has no match in the
mouse genome, and at the break in synteny in the mouse
genome. But there is no break in synteny at this locus in
the rat genome. Mouse-human breakpoint absent in the
human-rat comparison suggests the rearrangement is spe-
cific to the mouse lineage, i.e. mouse-specific breakpoint.
There are no segmental duplications at this locus in
human and rat genomes after search of human and rat
segmental duplication databases. Fluorescent in situ
hybridization (FISH) using a BAC containing mouse EST
for SAMD9L (Estm25) revealed a single strong signal at
6A1-A2 in mouse chromosome 6 [28]. Since the sequence
of  Estm25 maps to the open reading frame of mouse
Diagram for the genomic region encompassing the loci of SAMD9 and SAMD9L in human, mouse and rat along with the seg- mental duplications Figure 7
Diagram for the genomic region encompassing the loci of SAMD9 and SAMD9L in human, mouse and rat along 
with the segmental duplications. Exons are shown as a red box. Segmental duplications are shown as orange, green, blue 
and grey boxes. Two orange segmental duplications may mediate chromosomal breakage with subsequent deletion of SAMD9, 
and the centromeres of chromosome 6 and 5 are formed at the sites of breakage. The grey segmental duplications, sharing the 
sequence among numerous centromeric loci, are accumulated at the centromere of chromosome 5. The green and blue seg-
mental duplications flanking the SAMD9L are mouse specific based on sequence similarity, while the orange and grey segments 
have occurred at about the same time as the divergence of mouse and rat.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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SAMD9L, and it has very high homology with the
sequence at the open reading frame of human SAMD9,
the FISH result indicates SAMD9 does not exist in mouse.
Here we propose a model, which is mouse specific, for the
genomic rearrangement, break in synteny, centromere for-
mation and deletion of SAMD9 although it is very difficult
to properly estimate all those events. We highlight a
mouse specific rearrangement, resulting in the loss of the
SAMD9 gene. Segmental duplications have been shown to
mediate chromosomal rearrangements via non-allelic
homologous recombination [30], and it has been shown
that there is a significant correlation between low copy
repeats and break of synteny between human and mouse
[31]. Taken together, the existence of the mouse specific
rearrangement and mouse specific low copy repeats, it
would suggest a causative role, but no direct conclusions
can be made. It has also been shown that centromeric
regions act as reservoirs for recently duplicated sequence
and this may account for the enrichment of low copy
repeats at this locus [32]. As shown in Figure 7, in the
mouse genome, two segmental duplications, one centro-
meric to cdk6 and the other centromeric to SAMD9L, may
mediate chromosomal breakage with subsequent deletion
of SAMD9, and the centromeres of mouse chromosome 6
and 5 are formed at the sites of breakage. There is no evi-
dence of the segmental duplications at this locus in the rat
genome after searching the Evan Eichler's rat segmental
duplication database [33].
Conclusion
SAMD9  and  SAMD9L  are expressed ubiquitously in
human tissues, but they are expression at lower levels in
neoplasia. SAMD9 regulates cell proliferation and apop-
tosis, and decreases tumor growth of colon cancer cell line
in immune deficient mice. This is the first report as far as
we know about a human gene that exists in rat, but is lost
in mouse, due to a mouse specific rearrangement, result-
ing in the loss of the SAMD9 gene. Although these novel
genes were identify in the study of a relatively rare disor-
der, aggressive fibromatosis, these genes seem to play a
role regulating cell growth in a variety of tumor types.
Methods
Cell lines, human and mouse materials
SW480, MRC-5, Cos-1 and NIH3T3 cell lines were
obtained from the American Tissue and Cell Collection.
For each experiment in which cell lines were used for a
quantitative assay, the experiment was conducted nine
independent times, each time on a different day. The RNA
populations used for subtractive hybridization were pre-
pared from cells derived from an aggressive fibromatosis
tumor with an APC mutation after transfection of wild-
type APC or a control vector as previously reported [11].
Cells, tumor and normal control tissues were collected
from patients with sporadic aggressive fibromatosis,
colon cancer, and breast cancer while the patients were
under surgical excision of the tumors. All of the samples
were cryopreserved as soon as possible after resection and
stored in liquid nitrogen vapor for later nucleic acids
extraction. The local ethical approvals for this research
were obtained.
Suppression subtractive hybridization
Suppression subtractive hybridization was used to com-
pare the gene expression differences in a cell culture
derived from an aggressive fibromatosis tumor with an
APC mutation after transfection of a wild type APC to the
same cell culture after transfection of a control vector
using Clontech PCR-select cDNA subtraction kit (K1804-
1, Clontech, CA, USA). Both forward (cDNA from cells
transfected with control vector was subtracted by cDNA
from cells transfected with wild-type APC) and reverse
(cells transfected with wild-type APC was subtracted by
cells transfected with control vector) subtractions were
conducted. There were eight genes identified in the for-
ward subtraction and 16 genes in the reverse subtraction
that were found to be differentially expressed, based on
the screening of dot blots containing 196 clones in the for-
ward and reverse subtracted libraries, respectively. SAMD9
was confirmed as being differentially expressed in the
reverse subtraction and selected for further analysis in this
paper.
Northern analysis
15 μg of total RNA from 8 weeks, 12 weeks and full term
human placenta were electrophoresed on 1% RNase-free
agarose gel and Northern transferred to a nylon mem-
brane according to according to the method from Sam-
brook et al [34]. A probe for SAMD9 was generated using
PCR with 89729F and 88001R as primers for a 1729 bp
fragment from the 3'UTR. The Northern membrane was
first probed with the SAMD9, then stripped and probed
with the human actin probe as a loading control. The
probes were labeled with isotope 32P.
Cloning of the full-length gene
(1) 5'- and 3'- rapid amplification of cDNA ends (RACE)
RACE was performed using SMART™ RACE cDNA synthe-
sis kit (Clontech Inc., USA) according to the manufac-
ture's instruction. The anti-sense (93769R, see Additional
file 1) and the sense (93961F, see Additional file 1) prim-
ers for the 5'- and 3'- RACE were designed using the
sequence of the 200 bp clone of SAMD9 isolated from
suppression subtractive hybridization. The amplified
transcripts were cloned into a pCR 2.1 vector (Invitrogen,
USA), sequenced, and mapped to the DNA sequence in
the GenBank.BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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(2) Long-distance PCR, cloning and sequencing
Sequences corresponding to the 5'- and the 3'- ends of the
SAMD9 gene (106430F' and 87926R', see Additional file
1) or SAMD9L gene (136752F' and 119170R', see Addi-
tional file 1) were used as primers for long-distance PCR.
The amplified transcripts were cloned into a pCR vector
(Invitrogen, USA), and the insertion of the transcript was
verified by restriction enzyme digestion and sequencing.
PCR with human multiple tissue cDNA panels
Expression of SAMD9 and its paralogous gene SAMD9L
were investigated using PCR of human multiple tissue
cDNA panels including adult, fetal and tumor tissues
(Clontech, USA). The sequences at the 3' UTR of the
SAMD9 and SAMD9L genes were used to design the target
primers according to the instruction from the manufac-
ture since the DNase pretreated RNA was used for synthe-
sis of those cDNA panels. 88347F and 88001R [see
Additional file 1] were primers for SAMD9, while
119622F and 119170R [see Additional file 1] for
SAMD9L. GAPDH was used as a control.
Semi-quantitative RT-PCR
The total RNA was extracted from tumor tissue and nor-
mal control tissue from aggressive fibromatosis, breast
and colon cancers using Trizol RNA reagents (Invitrogen,
USA). The anti-sense and sense primers for SAMD9 and
human beta-2 microglobulin (beta 2M) were designed
using the sequence across the introns, and beta 2M was
used as control. For beta 2M, beta 2M-F was used as sense
primer and beta 2M-R as anti-sense primer to produce a
112 bp PCR product [see Additional file 1]. For SAMD9,
103270F was used as sense primer and 93871R as anti-
sense primer to produce a 711 bp PCR product for SAMD9
with SAM domain coding sequence and a 222 bp PCR
product for SAMD9 lacking SAM domain coding sequence
[see Additional file 1]. The optimal amplification cycles
were set within the linear range, 30 cycles for beta 2M and
37 cycles for SAMD9, after applying series of diluting
cDNA samples and subjecting for series of PCR amplifica-
tion cycles.
The polymerase cycling reactions of paired cDNA samples
were conducted at the same time for both target and con-
trol genes. The amplified products were electropheresed
on a 2% agarose gel and photographed under UV light.
The expression of beta 2M was set as control to normalize
the level of target expression. The expression level of the
target gene SAMD9 was analyzed using computer software
ImageQuant and represented as the ratio of its intensity
verse the intensity of the beta 2M gene under the condition
that the same amount of the cDNA was applied as tem-
plate for the target gene and the control gene.
Real-time quantitative PCR
Real-time quantitative PCR was undertaken using 28S
rRNA (28S) as the control gene. PCR primer pairs for
human 28S rRNA were taken from Simpson et al, 2000
[35], for SAMD9, 103270F was used as sense primer and
94424R as anti-sense primer, and for SAMD9L, 133857F
was used as sense primer and 124170R as anti-sense
primer [see Additional file 1]. Validation curves were car-
ried out for the primer sets using RNA from SW480 cells
diluted to 1:5, 1:10, 1:50, 1:100, and 1:1000. Delta delta
Ct method was used for setting up the experiment and
analysis of the data. An arbitrarily designed threshold was
set at 0.2 for all analysis, while the baseline cycles were set
for all analysis from 3 to 10 cycles for 28S and from 3 to
30 cycles for SAMD9 or SAMD9L. The threshold cycle, Ct
was determined using the analysis software (SDS 2.1,
Applied Biosystems). The result was analyzed using the
relative quantitative 2-ΔΔ C 
t method [36]. The expression
level of the target gene SAMD9 or SAMD9L in tumor tis-
sues were represented as the fold difference from normal
control tissues.
Generation of expression vectors
(1) Long distance PCR amplification of SAMD9 or SAMD9L open 
reading frame
The sequences flanking the predicted open reading frame
of the SAMD9 or SAMD9L gene were used as primers. For
SAMD9, 94504F was the sense primer and 89735R was
the anti-sense primer, while 124378F as sense primer and
119624R as anti-sense primer for SAMD9L  [see Addi-
tional file 1]. The predicted open reading frame of the
SAMD9 or SAMD9L was subcloned into pDNR-1r donor
vector using standard methods [34]. The correct orienta-
tion of the insert was confirmed by restriction enzyme
digestion and sequencing to generate pDNR-1r-SAMD9-
ORF, pDNR-1r-SAMD9L-ORF-major and pDNR-1r-
SAMD9L-ORF-minor.
The pDNR-1r-SAMD9-ORF, pDNR-1r-SAMD9L-ORF-
major and pDNR-1r-SAMD9L-ORF-minor were sub-
cloned into several acceptor vectors, such as pLP-EGFP-C1
and pLP-CMV-HA (Clontech, USA), using Clontech Crea-
tor™ DNA cloning kit (PT3460-2, Clontech, USA) with
Cre recombinase through Cre-loxP site-specific recombi-
nation to catalyze the transfer of the open reading frame
from pDNR-1r donor vector to the acceptor vectors
according to the manufacture's instruction.
Western blot analysis with anti-GFP
The total protein from Cos-1 cells transfected with either
pLP-EGFP-SAMD9 or its control vector pLP-EGFP were
harvested using Nonidet P-40 lysis buffer (1% Nonidet P-
40, 50 mM Tris-HCL [pH 7.5], 150 mM NaCl, 2 mM
EDTA, 10% glycerol, proteinase inhibitor tablet [1 tablet
per 10 mL buffer, Roche, USA]). The protein was electro-BMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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pheresed on 8% sodium dodecyl sulphacrylamide gel and
transferred to membrane according to the method from
Sambrook et al, 1989. The membrane was then probed
with anti-GFP (1:200, Santa Cruz, USA) and secondary
antibody (HRP-conjugated monoclonal anti-mouse IgG,
1:2000, Transduction Laboratory, USA). Finally, the
membrane was exposed to X-ray film for 20 minutes. The
total protein from Cos-1 cells transiently co-transfected
with pLP-EGFP-SAMD9 and either one of the two SAMD9
RNA interference vectors (pSUPER-RNAi-SAMD9, pSU-
PER-RNAi-SAMD9-2nd), RNA interference vector with
mutated  SAMD9  sequence (pSUPER-RNAi-SAMD9-
mut9) to null its function as negative control, or its con-
trol empty vector (pSUPER-RNAi-EGFP) were also har-
vested for Western blot analysis to confirm the knock-
down of SAMD9 expression by RNA interference.
Generation of RNA inference vector for SAMD9
After searching of the public available sequence database,
a 19 bp oligonucleotide sequence (846 bp after the start
of translation) specific for the RNA inference of the
SAMD9  expression was found (5'-GTGCATTCGA-
GAGCCAAGA-3') and subcloned into a pSUPER-RNAi-
EGFP expression vector to generate the SAMD9 RNA inter-
ference vector (pSUPER-RNAi-SAMD9). A nucleotide sub-
stitution from G to A at the 9th position of this 19 bp
oligonucleotide results in abolishing of its specificity to
SAMD9 to generate the negative control vector (pSUPER-
RNAi-SAMD9-mut9). Another 19 bp oligonucleotide
sequence (2371 bp after the start of translation) specific
for the RNA inference of the SAMD9 expression was found
(5'-TACGTACCTGTACTACTCC-3') and also subcloned
into a pSUPER-RNAi-EGFP expression vector to generate a
second SAMD9 RNA interference vector (pSUPER-RNAi-
SAMD9-2nd).
Cell culture, gene transfection, selection, flow cytometry 
cell sorting, immunoflurescent staining and confocal 
microscopy
SW480, MRC-5, or Cos-1 cells (ATCC, USA) were cultured
in the DMEM medium with 10% fetal calf serum (Invitro-
gen, USA) in a CO2 incubator at 37°C. Gene transfection
was conducted using Fugene 6 reagent (Roche, USA). The
transfected cells were either harvested for transient trans-
fection or selected with the addition of 200 ng of G418
(Sigma, USA) for 2 weeks, and sorted by flow cytometry
using GFP as marker. The cellular location of SAMD9 was
analyzed under a confocal microscope in Cos-1, MRC-5
and SW480 cells transfected with pLP-EGFP-SAMD9. The
effectiveness of SAMD9  RNA interference was docu-
mented by using confocal microscopy in SW480 cells co-
transfected with pLP-CMV-HA-SAMD9 and either the
SAMD9 RNA interference vector (pSUPER-RNAi-SAMD9)
or its empty control vector (pSUPER-RNAi-EGFP), which
were fixed, stained with anti-HA (1:200, Santa Cruz, USA)
and Tex-red conjugated secondary antibody (1:100,
Molecular Probes, USA).
In vitro assays
(1) Cell proliferation assay
Cells were seeded at the 2.5 × 104 cells/mL on glass cover
slips and cultured in DMEM with 10% fetal bovine serum
at 37°C. S-phase cells were labelled overnight by supple-
mentation of the cell culture medium with BrdU (Sigma,
St louis, MO; 10 μM) and detected by mouse monoclonal
anti-BrdU (DAKO, Demark; 1:100) as the published
method [37]. After the final step, the glass cover slips were
removed from the well and mounted on microscope
slides by mounting medium with DAPI to stain the nuclei.
The number of S-phase cells and total number of nuclei
were counted over five fields at center and four corners on
the glass cover slip at 100× magnification. Each experi-
ment was conducted nine times.
(2) Cell motility and invasion assays
Cells were seeded at 5 × 104 cells/mL and cultured with
DMEM and 10% fetal bovine serum for 22 hours at 37°C
in the BioBoat® culture inserts (BD Bioscience) for motility
assay and BioBoat® Matrigel invasion chambers (BD Bio-
science) for invasion assay. After the incubation period,
cells on the upper surface of the membrane were removed,
but cells that migrated to the lower surface of the mem-
brane were fixed to the membrane with 4% paraformalde-
hyde. The membranes were then excised from the insert
and mounted on microscope slides by mounting medium
with DAPI to stain the nuclei. The total number of nuclei
was counted in each of five fields across the diameter of
the member viewed at 400× magnification using UV fluo-
rescence microscopy. The experiments were conducted
nine times.
(3) Cell apoptosis assay
Cell apoptosis activity was studied using caspase-3 colori-
metric activity assay kit (Chemicon International, USA).
The experiments were conducted nine times and relative
caspase-3 activity was represented as percentage changes
of the treatment group to the control group and calculated
by dividing the optical density reading of the treatment
group to the control group and multiplying 100.
Xenograft in immune deficient mice
(1) SW480
The flow cytometry sorted SW480 cells transfected with
either pLP-EGFP-SAMD9 or its control vector pLP-EGFP
were suspended in 1× PBS (120 mM NaCl, 10 mM
Na2HPO4, 3 mM KH2PO4, pH 7.3) and injected under-
neath the skin on the back of nude mice and NOD-SCID
mice at a concentration of 2.5 million cells per injection.
A similar explant was performed using sorted SW480 cells
co-transfected with pLP-CMV-HA-SAMD9 and theBMC Genomics 2007, 8:92 http://www.biomedcentral.com/1471-2164/8/92
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SAMD9 RNA interference vector (pSUPER-RNAi-SAMD9)
or pLP-CMV-HA-SAMD9 and the empty control vector
(pSUPER-RNAi-EGFP). The mice were sacrificed after 1
week of injection and the size of tumors were blindly
scored.
(2) MRC-5
The flow cytometry sorted MRC-5 cells transfected with
the  SAMD9  RNA interference vector (pSUPER-RNAi-
SAMD9) or the empty control vector (pSUPER-RNAi-
EGFP) were also suspended in 1× PBS and injected under-
neath the skin on the back of NOD-SCID mice at a con-
cerntration of 5.9 million cells per injection. The mice
were sacrificed after 1 week of injection and the size of
tumors were blindly scored.
Statistical analysis
The counting process was conducted by a blinded
observer. Means and 95% confidence intervals were calcu-
lated. The t-test was applied to compare differences.
New sequence accession numbers
GenBank: AF445355, AF474973, AF453311, AY195582-
195587, DQ068177.
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